Abivax Shares Drop Below €100 After a 1,600% Surge Over the Year
The stock of the French biotech company significantly lost ground this Thursday, in a pressured Parisian market. Abivax fell by 4.41% to €97.50, dropping below the symbolic threshold of €100 while the CAC 40 index declined by 1.25% during the session. This drop comes after a week that was slightly positive for the stock, which had still shown a gain of 1.78% over the past seven days.
Technical Indicators Show Weakening Short-Term Momentum
Abivax's stock price is now below its 20-day moving average (€99.53) and its 50-day moving average (€101.11), both signals indicating a weakening of short-term momentum. However, the 200-day moving average, positioned at €79.37, remains well below the current price, reflecting the maintenance of a strong underlying upward trend: over the year, the cumulative performance exceeds 1,600%. The RSI, at 52, is in a neutral zone and does not indicate either overbuying or overselling. Monthly volatility remains particularly high at 56.40, while a beta of 3.58 confirms the stock's heightened sensitivity to general market movements. In a context where the CAC 40 significantly retreats during the session and the SBF 120 loses 1.26%, this characteristic partly explains the magnitude of today's correction. The technical support identified at €88.80 is the next level to watch if the decline continues, while resistance is formed around €112.40. In the sector, other European pharmaceutical stocks are also experiencing sell-offs: Sanofi is down 0.74% and UCB loses 3.14%, in a market environment generally unfavorable to risk assets.
Upcoming Quarterly Results Scheduled for June 1, 2026
Abivax's next quarterly results are scheduled for June 1, 2026, a date that will focus attention on the progress of the clinical pipeline and the company's cash consumption. The half-year results will follow on September 14, and then the third-quarter results on December 14. The first-quarter publication will be particularly scrutinized given the stock's spectacular trajectory over the past twelve months, with a price increase of more than 17 times since April 2025. Over three months, however, the trend is less favorable: Abivax shows a decline of 19.02%, indicating a consolidation phase after the previous sharp rise. The lack of immediate catalysts, combined with an uncertain macroeconomic environment — geopolitical tensions in the Middle East fueling nervousness on global financial markets — contributes to maintaining selling pressure on high-beta stocks. Thursday's session illustrates the particular sensitivity of a biotech of this size to overall market movements, with the next fundamental milestone two months away.
